Already a big seller, Boehringer Ingelheim GmbH's Jardiance looks set to become a mega-blockbuster as the diabetes drug's expansion into heart failure, and very probably kidney disease, brings in millions more patients and millions more euros.
Sales of Jardiance (empagliflozin) in 2021 were boosted by significant label expansions which made the SGLT2 inhibitor, initially approved in...








